Overview

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to determine the safety of intravenous MN-221 compared to placebo when administered in subjects diagnosed with stable moderate to severe COPD.
Phase:
Phase 1
Details
Lead Sponsor:
MediciNova